Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

about

Elvitegravir for the treatment of HIV.

P2860

Q38987327-A52D33CB-424D-4E41-94A5-E36C73659095

P2860

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

Item

http://www.wikidata.org/entity/Q40593858

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

@en

type

Item

label

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

@en

prefLabel

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

@en

P1476

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

@en

P2093

A D Kashuba

http://www.w3.org/2001/XMLSchema#string

A Imaz

http://www.w3.org/2001/XMLSchema#string

A Vila

http://www.w3.org/2001/XMLSchema#string

C Sykes

http://www.w3.org/2001/XMLSchema#string

D Podzamczer

http://www.w3.org/2001/XMLSchema#string

E Ferrer

http://www.w3.org/2001/XMLSchema#string

J Niubó

http://www.w3.org/2001/XMLSchema#string

L Acerete

http://www.w3.org/2001/XMLSchema#string

N Rozas

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of HIV-1 infection with early antiretroviral therapy

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

HIV-1 Populations in Semen Arise through Multiple Mechanisms.

Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission

Xenobiotic transporter expression along the male genital tract.

Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.

Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV.

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

P304

225-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HIV.12417

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27477062

http://www.w3.org/2001/XMLSchema#string

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

about

P2860

P2860

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698